Axcelius I/II is a biopharmaceutical company-creation vehicle backed by Canaan Partners, formed to found and incubate drug-development companies pursuing treatments for cancer, rare diseases, and neurodegenerative disorders. It is led by managing partner Dennis Podlesak and sponsored at Canaan by general partner Brent Ahrens, and operates from San Francisco, California, with an associated holding entity registered in Connecticut at Canaan's Westport office. Rather than operating as a product company, Axcelius assembles management teams and capital around licensed therapeutic assets and spins them out as standalone biopharma companies; Transposon Therapeutics, developing therapies for ALS and Alzheimer's disease, is its best-documented creation. As of this enrichment pass the vehicle remains in stealth mode with no public developer surface -- no product website beyond a holding page, no documentation, developer portal, SDKs, GitHub organization, or API of any kind.
Axcelius I/II is profiled on the APIs.io network. Tagged areas include Company, Venture Capital, Company Creation, Biopharmaceutical, and Life Sciences.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: axcelius-i-ii
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source: []
generated: '2026-07-22'
method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/axcelius-i-ii.png
name: Axcelius I/II
description: Axcelius I/II is a biopharmaceutical company-creation vehicle backed by Canaan Partners, formed to found and
incubate drug-development companies pursuing treatments for cancer, rare diseases, and neurodegenerative disorders. It is
led by managing partner Dennis Podlesak and sponsored at Canaan by general partner Brent Ahrens, and operates from San Francisco,
California, with an associated holding entity registered in Connecticut at Canaan's Westport office. Rather than operating
as a product company, Axcelius assembles management teams and capital around licensed therapeutic assets and spins them
out as standalone biopharma companies; Transposon Therapeutics, developing therapies for ALS and Alzheimer's disease, is
its best-documented creation. As of this enrichment pass the vehicle remains in stealth mode with no public developer surface
-- no product website beyond a holding page, no documentation, developer portal, SDKs, GitHub organization, or API of any
kind.
url: https://raw.githubusercontent.com/api-evangelist/axcelius-i-ii/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: stealth-company-creation-vehicle-no-public-api-surface
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Venture Capital
- Company Creation
- Biopharmaceutical
- Life Sciences
- Drug Discovery
- Oncology
- Rare Disease
- Neurodegenerative Disease
- Stealth
apis: []
common:
- type: DomainSecurity
url: security/axcelius-i-ii-domain-security.yml
- type: Website
url: https://axcelius.com/
x-verification: Unconfirmed attribution. axcelius.com serves only a 386-byte "AXCELIUS" holding page (HTTP 200, GoDaddy
hosting). Registered 2019-07-31, three weeks before Axcelius Holding Company, LLC was registered in Connecticut (2019-08-20)
at Canaan Partners' Westport office; WHOIS registrant is privacy protected. Timing and naming corroborate but do not prove
the association.
- type: InvestorProfile
url: https://www.canaan.com/companies/axcelius-i-ii
x-enrichment:
date: '2026-07-20'
status: minimal
artifacts_added: 2
pass: local-v1
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →